Hanmi grew 33.4 percent in September

Published: 2004-10-19 06:59:00

Updated: 2004-10-19 06:59:00

The value by Hanmi Pharm in the outpatient prescription sector in September grew 33.4 percent, to 18.7 billion won, compared with the same month of last year, due to strong demand of its first generic version of Norvask plus Amaryl generic, a local report said recently.

The combined prescripti...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK